GlassScriptPhysician profile
Yacoub Sallam
NPI 1407333065
$630.92
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $263 · 2021: $139 · 2022: $27.24.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $151.27 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.12 | 2019-2021 | |
| Insmed, INC. | $117.50 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $66.01 | 2019-2021 | |
| Abbvie INC. | $63.46 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.37 | 2019-2021 | |
| Pfizer INC. | $25.60 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $23.75 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.84 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yacoub Sallam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.